{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T03:15:23Z","timestamp":1771298123397,"version":"3.50.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,20]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Anti-melanoma differentiation associated gene 5 antibody (anti-MDA5 Ab)-positive dermatomyositis (DM) is a representative of rapidly progressive interstitial pneumonia. However, its association with thrombotic microangiopathy (TMA), characterized by thrombocytopenia, haemolytic anaemia, and organ dysfunction, has not been defined. This study aimed to elucidate the characteristics of anti-MDA5 Ab-positive DM accompanied by TMA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We reviewed our hospital records from November 2009 to September 2022. We included patients in accordance with the 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria and the criteria of Bohan and Peter. TMA was diagnosed according to the criteria for transplantation-associated TMA proposed by the International Working Group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This study enrolled a total of 26 anti-MDA5 Ab-positive DM patients, four of whom developed TMA. The patients with TMA had an increased urine protein\/creatinine ratio. In addition, these four of them showed significantly elevated levels of ferritin and anti-MDA5 Ab titers and were considered to have high disease activity; yet, all of them survived.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study indicated that anti-MDA5 Ab-positive DM patients with hyperferritinemia, a high anti-MDA5 Ab titer, and an increased urine protein\/creatinine ratio should be carefully managed, bearing in mind a complication of TMA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roae009","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T12:55:28Z","timestamp":1706878528000},"page":"973-977","source":"Crossref","is-referenced-by-count":3,"title":["Characteristics of anti-melanoma differentiation associated gene 5 antibody-positive dermatomyositis with thrombotic microangiopathy"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5678-8138","authenticated-orcid":false,"given":"Toshiyuki Shiki","family":"Ushijima","sequence":"first","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5890-3606","authenticated-orcid":false,"given":"Toshihiko","family":"Komai","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Izuka","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Shoda","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keishi","family":"Fujio","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"2024101507120396700_R1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima","year":"2010","journal-title":"Rheumatology"},{"key":"2024101507120396700_R2","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","article-title":"Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients","volume":"57","author":"Sato","year":"2018","journal-title":"Rheumatology"},{"key":"2024101507120396700_R3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00296-022-05214-0","article-title":"Long-term risks of malignancy in myositis-specific antibody-positive idiopathic inflammatory myopathy","volume":"43","author":"Izuka","year":"2023","journal-title":"Rheumatol Int"},{"key":"2024101507120396700_R4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.amjms.2017.07.013","article-title":"Clinical heterogeneity of interstitial lung disease in polymyositis and dermatomyositis patients with or without specific autoantibodies","volume":"355","author":"Chen","year":"2018","journal-title":"Am J Med Sci"},{"key":"2024101507120396700_R5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1684\/ejd.2020.3750","article-title":"Anti-Mi-2 antibodies characterize a distinct clinical subset of dermatomyositis with favourable prognosis","volume":"30","author":"Liang","year":"2020","journal-title":"Eur J Dermatol"},{"key":"2024101507120396700_R6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2024101507120396700_R7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2169\/internalmedicine.49.2706","article-title":"Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008","volume":"49","author":"Fujimura","year":"2010","journal-title":"Intern Med"},{"key":"2024101507120396700_R8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature","volume":"49","author":"Kello","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2024101507120396700_R9","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.2169\/internalmedicine.0512-17","article-title":"Thrombotic microangiopathy with polymyositis\/dermatomyositis: three case reports and a literature review","volume":"57","author":"Yamada","year":"2018","journal-title":"Intern Med"},{"key":"2024101507120396700_R10","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024101507120396700_R11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2024101507120396700_R12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group","volume":"92","author":"Ruutu","year":"2007","journal-title":"Haematologica"},{"key":"2024101507120396700_R13","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/TP.0b013e3181f24e8d","article-title":"Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation","volume":"90","author":"Cho","year":"2010","journal-title":"Transplantation"},{"key":"2024101507120396700_R14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1751-553X.2011.01380.x","article-title":"ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes","volume":"34","author":"Zini","year":"2012","journal-title":"Int J Lab Hematol"},{"key":"2024101507120396700_R15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4274\/tjh.2016.0359","article-title":"The clinical significance of schistocytes: a prospective evaluation of the international council for standardization in hematology schistocyte guidelines","volume":"34","author":"Schapkaitz","year":"2017","journal-title":"Turk J Haematol"},{"key":"2024101507120396700_R16","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology"},{"key":"2024101507120396700_R17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1191\/0961203302lu224oa","article-title":"Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: disease activity and the use of cytotoxic drugs","volume":"11","author":"Vasoo","year":"2002","journal-title":"Lupus"},{"key":"2024101507120396700_R18","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024101507120396700_R19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"key":"2024101507120396700_R20","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/bjd.16917","article-title":"Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis","volume":"180","author":"Zhang","year":"2019","journal-title":"Br J Dermatol"},{"key":"2024101507120396700_R21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10157-007-0466-7","article-title":"Pathogenesis and prognosis of thrombotic microangiopathy","volume":"11","author":"Nangaku","year":"2007","journal-title":"Clin Exp Nephrol"},{"key":"2024101507120396700_R22","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.2169\/internalmedicine.8311-21","article-title":"Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial pneumonia presenting with nephrotic syndrome during treatment with corticosteroids and cyclosporine","volume":"61","author":"Kawamoto","year":"2022","journal-title":"Intern Med"},{"key":"2024101507120396700_R23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roae009\/56819823\/roae009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/5\/973\/59755485\/roae009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/5\/973\/59755485\/roae009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T07:13:00Z","timestamp":1728976380000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/5\/973\/7606449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,2,7]]},"published-print":{"date-parts":[[2024,8,20]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roae009","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,2,7]]}}}